

BIOGRAPHICAL SKETCH
Complete for each professional associated with the project

Name: [<i>Last, First, Middle Initial(s), Degree(s)</i>] Giorgia Teresa Maniscalco	Position/Title: M.D. Neurologist
---	-------------------------------------

Education

[Begin with baccalaureate or other professional education and include postdoctoral training]

Institution and Location	Degree	Year Conferred	Field of Study
Second University of Naples (SUN)	MD	22.07.2002	Research Thesis on "Influence of treatment with azathioprine on prognostic factors in RRMS: a retrospective comparative study with the natural history of the disease."
Second University of Naples (SUN)	Neurologist	26.11.2007	Research Thesis on "The suspension of the disease-modifying drugs in patients with RRMS"

Research and Professional Experience

[List in chronological order, previous employment, experience and honors]

Position and Honors

- 2002-2007** Resident in Neurology at University of Naples "Second University SUN"
- 2007-2008**: Neurologist at Multiple Sclerosis Center of Second University of Naples (SUN)
- 2008-2015**: Neurologist at Multiple Sclerosis Center of "A. Cardarelli" Hospital of Naples
- 2015 to date**: MD Neurologist at the UOSC of Neurology and Stroke Unit at "A. Cardarelli" Hospital
- 2014**: Technical Advisor to the Scientific Committee of the project "Health Economics and management tools to support the implementation of the diagnostic therapeutic process of care (PDTA) and network among centers for the diagnosis and treatment of multiple sclerosis (MS) in Campania".
- 2008 to date**: Principal investigator and co-investigator in several Phase III and IV clinical trials on Multiple Sclerosis

Number pages consecutively throughout the

2

Revised 6/08

Publications

For each investigator, provide complete bibliographic citations for selected **publications related to the topic of this application**. DO NOT exceed one page for each individual.

1. "Listerial rhombencephalitis: an unusual clinical course", Neurological Sciences, suppl. Vol. 26 October 2005
2. "TNF-alfa and IGF-1 variation in relapsing-remitting multiple sclerosis patients before and after one year treatment with high dose of INF beta 1^o"; Multiple Sclerosis, suppl. Vol. 12, September 2006
3. "TNFAlpha and IGF variation in RR MS patients before and after one year treatment with high dose of INF beta 1a"; Neurological Science, suppl. Vol. 27 October 2006
4. "Miglioramento dei parametri di risonanza magnetica in una paziente affetta da Sclerosi Multipla e trattata con Natalizumab"; MS overview in practice, suppl. n.3 October 2008
5. "Treatment withdrawal in relapsing remitting MS: an observational retrospective study"; Neurological Science, suppl. Vol. 29, October 2008
6. "Tumor necrosis factor-alpha and insulin-like factor-1 levels in patients with relapsing-remitting multiple sclerosis receiving interferon-beta 1a"; Journal of Interferon and Cytokine Research, Vol. 29 n.5 May 2009
7. "Sclerosi multipla e osteoporosi: screening densitometrico di donne affette da sclerosi a placche"; Europa Medicophysica Semtember 2009; 45 (suppl. 1 to n.3)
8. "Qualità della vita correlata alla salute nella sclerosi multipla : effetti del trattamento riabilitativo", Medicina 2000, suppl. Vol. XVI fascicolo 1; Gennaio 2010
9. "Effetti del trattamento con Natalizumab sul sintomo fatica nei pazienti affetti da sclerosi multipla", Medicina 2000, suppl. Vol. XVI fascicolo 1; Gennaio 2010
10. "Impatto della terapia con Mitoxantrone sulla qualità di vita nei pazienti affetti da sclerosi multipla secondaria progressiva", Medicina 2000, Vol. XVI fascicolo 1; Gennaio 2010
11. Improvement of visual acuity in patients with severe visual loss affected by multiple sclerosis treated with natalizumab: a case report. Neurol Sci. 2011 Jan;31 Suppl 3:325-7. Review
12. "A volte ritornano": Gerstmann's Syndrome , a case report Neurol Sci 2012 Oct Vol 33 Suppl 205.
13. "Retrospective person year study for current state of patients receiving Glatiramer Acetate in Campania-Molise in 2012" ; Neurol Sci 2013 Oct Vol 34 Suppl 391
14. "Patient adherence to and tolerability of self-administered interferon β -1a using an electronic autoinjection device: a multicentre, open-label, phase IV study" BMC Neurol. 2012 Mar
15. "Natalizumab treatment in multiple sclerosis patients: a multi center experience in clinical practice in Italy" Int J Immunopathol Pharmacol 2014 Apr-Jun
16. "Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study." J Neurol. 2015 Apr
17. "The Framingham cardiovascular risk score in multiple sclerosis". Eur J Neurol. 2015 Apr .
18. "Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate". Metabolism. 2015 May , S0026-0495.
19. "Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Mult Scler 2015 Sep
20. "Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β -1a using an electronic device: the RIVER study". Expert Opin Drug Deliv. 2016 Feb
21. "No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β 1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)". Mult Scler. 2015 Oct
22. "The management of multiple sclerosis by reference centers in south of Italy: a 2011 survey on health demands and needs in Campania region". Neurol Sci. 2016 Feb
23. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat Immunol. 2015 Nov
24. Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study. Eur J Neurol. 2016 Mar
25. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β -1a using an electronic device: the RIVER study. Expert Opin Drug Deliv. 2016 Feb
26. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016 May

Firma
